Clinical Trial Update: Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) [Phase 1]

View source ↗

Summary

The update reports on tolerability of adding Ropeginterferon alfa-2b to ongoing ruxolitinib therapy in patients with myelofibrosis in a Phase 1 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ropeginterferon alfa-2b (ropeginterferon alfa-2b)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Utah | Conditions: Myelofibrosis | Phase 1 | Status: NOT_YET_RECRUITING